Dr. Bart Tarbet received his Ph.D. in Animal Science from the University of Delaware, with specialization in pathology (pathogenesis of infectious disease). His M.S. degree in Microbiology and Immunology was completed at the Louisiana State University Medical Center, and his undergraduate work in Microbiology was done at Weber State University. He joined the Institute for Antiviral Research at Utah State University in 2008. Prior to joining USU, Dr. Tarbet was employed in Research and Development at Intervet Inc. (now Merck Animal Health), a global leader in the discovery, development, and manufacture of veterinary medicines. During the twelve years that he worked at Intervet he completed proprietary research in the area of vaccine development. Vaccine projects for which he was responsible included: both live- and killed-influenza virus vaccines, recombinant [subunit and live-chimera] vaccines, and a live-attenuated bacterin. In addition, his research included cell culture scale up to bioreactors, vaccine adjuvant selection, and technology transfer from R&D to Production.

In addition, Dr. Tarbet is co-director of a training course in the manufacture of influenza virus vaccines developed for countries supported by the BARDA / WHO international vaccine production capacity building program, and is on the Editorial Boards of the Journal of Virology & Antiviral Research and Antiviral Chemistry & Chemotherapy.

Dr. Tarbet has broad interests in virology, immunology, and antiviral chemotherapy. Current research includes animal models of influenza virus infection and evaluation of experimental therapies and vaccines for use against influenza virus.